Global", or "the Company") announced today that it entered into an exclusive letter of intent with the University of California, San Francisco to negotiate an option agreement in regards to the exclusive global licensing of a medical stereotactic device which the Company believes has the potential to revolutionize the delivery of stem cells into ... (more)
http://www.macreportmedia.com/ViewSubmission.aspx?submissionRequest=25653
http://www.macreportmedia.com/ViewSubmission.aspx?submissionRequest=25653
No comments:
Post a Comment